Puma Biotechnology (PBYI) Total Non-Current Liabilities (2019 - 2025)

Puma Biotechnology's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $86.0 million for Q4 2025.

• Quarterly Total Non-Current Liabilities fell 29.01% year-over-year to $86.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $86.0 million (down 29.01% YoY) and the FY2025 annual result came in at $86.0 million, down 29.01% from the prior year.
• Total Non-Current Liabilities was $86.0 million for Q4 2025 at Puma Biotechnology, down from $87.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $242.0 million in Q1 2021 and bottomed at $86.0 million in Q4 2025.
• A 5-year average of $163.9 million and a median of $163.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities grew 16.27% — and 2025, when it plunged 41.41%.
• Puma Biotechnology's Total Non-Current Liabilities stood at $223.6 million in 2021, then fell by 10.36% to $200.4 million in 2022, then retreated by 11.7% to $177.0 million in 2023, then plunged by 31.58% to $121.1 million in 2024, then dropped by 29.01% to $86.0 million in 2025.
• Business Quant data shows PBYI's Total Non-Current Liabilities at $86.0 million in Q4 2025, $87.6 million in Q3 2025, and $90.2 million in Q2 2025.